Adverse effects of dopamine potentiation by long-term treatment with selegiline

Mov Disord. 2004 Jan;19(1):107-9. doi: 10.1002/mds.10641.

Abstract

A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anemia, Hemolytic, Congenital / enzymology
  • Anemia, Hemolytic, Congenital / genetics*
  • Antiparkinson Agents / adverse effects*
  • Antiparkinson Agents / therapeutic use
  • Baclofen / adverse effects
  • Baclofen / therapeutic use
  • Basal Ganglia / drug effects
  • Basal Ganglia Diseases / drug therapy
  • Basal Ganglia Diseases / enzymology
  • Basal Ganglia Diseases / genetics*
  • Blood Platelets / enzymology
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced / diagnosis
  • Dyskinesia, Drug-Induced / etiology*
  • Dystonia Musculorum Deformans / drug therapy
  • Dystonia Musculorum Deformans / enzymology
  • Dystonia Musculorum Deformans / genetics*
  • Female
  • Genetic Carrier Screening
  • Genotype
  • Glyceraldehyde-3-Phosphate Dehydrogenases / deficiency*
  • Glyceraldehyde-3-Phosphate Dehydrogenases / genetics
  • Humans
  • Huntingtin Protein
  • Long-Term Care
  • Male
  • Middle Aged
  • Monoamine Oxidase / blood
  • Monoamine Oxidase / genetics
  • Monoamine Oxidase Inhibitors / adverse effects*
  • Monoamine Oxidase Inhibitors / therapeutic use
  • Nerve Tissue Proteins / genetics
  • Neurologic Examination / drug effects
  • Neuroprotective Agents / adverse effects*
  • Neuroprotective Agents / therapeutic use
  • Nuclear Proteins / genetics
  • Polymerase Chain Reaction
  • Proteins / genetics
  • Psychoses, Substance-Induced / diagnosis
  • Psychoses, Substance-Induced / etiology*
  • Reference Values
  • Selegiline / adverse effects*
  • Selegiline / therapeutic use
  • Trinucleotide Repeats

Substances

  • Antiparkinson Agents
  • HTT protein, human
  • Huntingtin Protein
  • Monoamine Oxidase Inhibitors
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • Nuclear Proteins
  • Proteins
  • Selegiline
  • Glyceraldehyde-3-Phosphate Dehydrogenases
  • Monoamine Oxidase
  • Baclofen